Both companies have entered into a license and option agreement, as well as a securities purchase agreement, in connection with the collaboration.
Under the terms of the agreement, BioNTech will purchase $200m of Autolus’ US depositary shares in a private placement and will make a cash payment of $50m.
In exchange, BioNTech will be eligible to receive an up to mid-single-digit royalty of its autologous CD19 CAR T cell therapy, obe-cel, net sales, while Autolus retains full rights to the development and commercialisation of obe-cel.
